Association of genetically instrumented HMGCR inhibition with the therapeutic role of prostate cancer: a Mendelian randomization study and supporting in vitro experiments
HMGCR inhibition reduces the risk of PCa, and this protective effect is independent of its lipid-lowering action. Our findings provide strong genetic support for initiating RCTs to investigate the therapeutic potential of statins for partial PCa patients.
Authors
- Jingjun Mu
- Xiaojie Hao
Institutions
- Shanxi Provincial Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/fphar.2025.1701869
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00